Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27525744 | 0.88 | NLRP3 (0.59) | KDM4EALDH1A1MAPTHDAC1MAOA | |
| SCHEMBL9717422 | 0.86 | HDAC1 (0.51) | KDM4EALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL27596815 | 0.84 | HDAC1 (0.50) | KDM4EALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL8531291 | 0.84 | ERCC1 (0.56) | KDM4EALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL13415005 | 0.81 | TSHR (0.57) | KDM4EALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL7214903 | 0.80 | L3MBTL1 (0.49) | KDM4EALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL29792562 | 0.80 | L3MBTL1 (0.49) | KDM4EALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL12049502 | 0.79 | TRPV1 (0.53) | HDAC8KMT2ACHRNA7KCNH2 | |
| SCHEMBL27626476 | 0.79 | ABL1 (0.46) | KDM4EALDH1A1MAPTHDAC1HDAC8 | |
| SCHEMBL29644286 | 0.78 | KDM1A (0.50) | HDAC1HDAC8MAOBMAOAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005794-B2 | Production method for 2-fluoro-4-borono-L-phenylalanine, and precursor of 2-fluoro-4-borono-L-phenylalanine | STELLA PHARMA CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| CN-103391936-A | Anticancer agent | NAT UNIV CORP UNIV TOKYO | 2013-11-13 | — | — | CN | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7049312-B1 | Benzothiazinone and benzoxazinone compounds | ABBOTT GMBH & CO. KG (DE) | 2006-05-23 | — | — | US | disclosed |
| EP-1330457-B1 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | WYETH CORP (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1181282-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000075139-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-14 | — | — | WO | disclosed |
| EP-0997474-A1 | Antithrombotic agents | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005794-B2 | Production method for 2-fluoro-4-borono-L-phenylalanine, and precursor of 2-fluoro-4-borono-L-phenylalanine | NPR1, NPFFR2, NPFFR1 | KDM4E 4176/4885ALDH1A1 2574/4885MAPT 4531/4885 |
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | KDM4E 540/4885ALDH1A1 1194/4885MAPT 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.